MicroRNA-572 expression in multiple sclerosis patients with different patterns of clinical progression

Research output: Contribution to journalArticle

Abstract

Background: Demyelination and failure of remyelination are core mechanisms in the pathogenesis of multiple sclerosis (MS); the factor(s) modulating these processes are still mostly unknown. MicroRNA 572 (miR-572) is deregulated in MS and is suggested to targets neural cell adhesion molecule (NCAM), a glycoprotein involved in CNS reparative mechanisms. The aim of this study is to analyze miR-572 in patients with different clinical phenotypes of MS. Methods: qPCR quantification of miR-572 isolated from serum was performed in 16 primary progressive (PP), 15 secondary progressive (SP), 31 relapsing remitting (RR) MS patients and 15 sex-and age-matched healthy controls. Results: miR-572 expression was reduced overall in MS patients (pSp=0.491; p

Original languageEnglish
Article number148
JournalJournal of Translational Medicine
Volume13
Issue number1
DOIs
Publication statusPublished - May 7 2015

Keywords

  • Disability
  • microRNA
  • Multiple sclerosis
  • NCAM
  • Remyelination
  • Serum

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Fingerprint Dive into the research topics of 'MicroRNA-572 expression in multiple sclerosis patients with different patterns of clinical progression'. Together they form a unique fingerprint.

  • Cite this